Earendil: A Blueprint for a Multipolar Life Sciences Era
The $787M financing points to a new global architecture in biotech
False
The $787M financing points to a new global architecture in biotech
False
False
August 14, 2026
4 min read
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
August 13, 2026
8 min read
Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional
August 7, 2026
7 min read
Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier
August 6, 2026
8 min read
Six drug development leaders discuss smarter immunotherapy combinations, the enduring potential of small molecules, emerging modalities, and how cancer treatment could evolve over the next two decades
False
Affiliations:
Specialties:
Areas of Expertise:
4 Topic Commentaries
Earendil: A Blueprint for a Multipolar Life Sciences Era
Julio Frenk, MD, MPH, PhD
Global health policy and health systems
•Harvard University
Nalini Anand, JD, MPH
Global health policy and research administration
•Georgetown University
Andrew Forsyth, PhD
Global health research policy and analytics
•Fogarty International Center, National Institutes of Health
Cassidy R. Sugimoto, PhD
Science of science and science policy
•Georgia Institute of Technology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.